(Athorel) is an inhibitor of platelet aggregation. Lopirel (Athorel) selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
(Athorel) is used for the reduction of atherosclerotic events (myocardial infarction, ischaemic stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease.
Athorel is also used to associated treatment for these conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
|Clopidogrel Other Names||Clopidogrel, Clopidogrelum|
Both the active and inactive metabolites of clopidogrel are 98% protein bound in plasma. Studies in cows show clopidogrel 71-85.5% bound to serum albumin.
|Therapeutic Class||Anti-platelet drugs|
|Last Updated:||June 23, 2021 at 11:19 am|
The recommended dose of Lopirel (Athorel) is 75 mg once daily with or without food.
Generally Athorel is well tolerated. However, a few common side effects i.e. Influenza-like symptoms, headache, upper respiratory tract infection, dizziness, muscle and back pain, and rash may occur.
As with other anti-platelet agents, Athorel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery, or other pathological conditions. Athorel should be discontinued 7 days prior to surgery. Athorel should be used with caution in hepatically impaired patients who may have bleeding diatheses.
Concomitant use of Heparin, Warfarin and NSAIDs with Athorel should be undertaken with caution. Athorel potentiate the effect of Aspirin on collagen-induced platelet aggregation. The safety of chronic concomitant administration of Aspirin and Athorel has not been established.
- Take with or without food.
Volume of Distribution
The apparent volume of distribution of clopidogrel is 39,240±33,520L.
That half life of clopidogrel is approximately 6 hours following a 75mg oral dose while the half life of the active metabolite is approximately 30 minutes.
The clearance of a 75mg oral dose was 18,960±15,890L/h and for a 300mg oral dose was 16,980±10,410L/h.
Pregnancy & Breastfeeding use
Pregnancy: There are no adequate and well-controlled studies of Athorel in pregnant women. However, Athorel should be used during pregnancy only if clearly needed.
Lactation: Athorel is not recommended for use while breast-feeding. It is not known for sure whether Athorel is excreted in breast milk, although it is suspected that it is.
Athorel is contraindicated in patients with a hypersensitivity to the drug substance or any component of the product, and those with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
Use in children: Safety and effectiveness of Athorel in pediatric population have not been established.
In the event of over dosage no adverse effects were reported and no therapy was substituted.
Symptoms: Prolonged bleeding time and subsequent bleeding complications.
Management: May restore clotting ability with platelet transfusion.
Store at 25° C.